LANIFIBRANOR

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C19H15ClN2O4S2
Molecular Weight	434.916
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

OC(=O)CCCC1=CC2=CC(Cl)=CC=C2N1S(=O)(=O)C3=CC4=C(C=C3)N=CS4

InChI

InChIKey=OQDQIFQRNZIEEJ-UHFFFAOYSA-N

InChI=1S/C19H15ClN2O4S2/c20-13-4-7-17-12(8-13)9-14(2-1-3-19(23)24)22(17)28(25,26)15-5-6-16-18(10-15)27-11-21-16/h4-11H,1-3H2,(H,23,24)

HIDE SMILES / InChI

Molecular Formula	C19H15ClN2O4S2
Molecular Weight	434.916
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description

IVA-337 (LANIFIBRANOR), an indole sulfonamide derivative, is a pan peroxisome proliferator-activated receptor (PPAR) agonist. It is under investigation in Phase 2 clinical trials for non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, and type 2 diabetes.

Originator

Approval Year

Targets

Targets

Primary Target	Pharmacology	Condition	Potency
Peroxisome proliferator-activated receptor alpha 62	Agonist 2,678
Peroxisome proliferator-activated receptor delta 29	Agonist 2,678
Peroxisome proliferator-activated receptor gamma 111	Agonist 2,678

PubMed

PubMed

Title	Date	PubMed
No data available in table

Sample Use Guides

In Vivo Use Guide

800 mg/day.

Route of Administration: Oral

In Vitro Use Guide

LANIFIBRANOR (IVA-337) is a pan peroxisome proliferator-activated receptor (PPAR) agonist with EC50s of 1.5, 0.87 and 0.21 uM for human PPARa, PPARb and PPARg, respectively.

Substance Class	Chemical
Record UNII	28Q8AG0PYL
Record Status	`Validated (UNII)`
Record Version

Show entries

Name

Type

Language

LANIFIBRANOR

Official Name

English

Lanifibranor [WHO-DD]

Common Name

English

lanifibranor [INN]

Common Name

English

1H-INDOLE-2-BUTANOIC ACID, 1-(6-BENZOTHIAZOLYLSULFONYL)-5-CHLORO-

Systematic Name

English

IVA-337

Code

English

Showing 1 to 5 of 8 entries

Previous1 2Next

Show entries

Classification Tree

Code System

Code

Designated

FDA ORPHAN DRUG

470315

Positive

EU-Orphan Drug

EU/3/14/1361

Showing 1 to 2 of 2 entries

Previous1Next

Show entries

Code System

Code

Type

Description

DRUG BANK

DB14801

PRIMARY

FDA UNII

28Q8AG0PYL

PRIMARY

EVMPD

SUB184623

PRIMARY

EU-Orphan Drug

EU/3/14/1362(POSITIVE)

PRIMARY

On 19 November 2014, orphan designation (EU/3/14/1362) was granted by the European Commission to Inventiva, France, for 1-(6-benzothiazolylsulfonyl)-5-chloro-1H-indole-2-butanoic acid for the treatment of idiopathic pulmonary fibrosis.

NCI_THESAURUS

C166556

PRIMARY

Showing 1 to 5 of 9 entries

Previous1 2Next

Show entries

Related Record

Type

Details


					AL17N8ZSWL

PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA

TARGET -> AGONIST


					2PDN1S3FVX

PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA

TARGET -> AGONIST

Interaction Type:

AGONIST

Qualification:

EC50

Amount:

RELATIONSHIP_AMOUNT 0.9 MICROMOLAR (average)


					L1Q8TMD5IZ

PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR DELTA

TARGET -> AGONIST

Interaction Type:

AGONIST

Qualification:

EC50

Amount:

RELATIONSHIP_AMOUNT 0.5 MICROMOLAR (average)

Showing 1 to 3 of 3 entries

Previous1Next

Show entries

Related Record

Type

Details


					28Q8AG0PYL

LANIFIBRANOR

ACTIVE MOIETY

Comments:

RESULTS: In mice, IVA337 was associated with decreased extracellular matrix (ECM) deposition and reduced expression of phosphorylated SMAD2/3-intracellular effector of transforming growth factor (TGF)-.BETA.1. Although the antifibrotic effect of pan PPAR was similar to that of PPAR.GAMMA. agonist alone, a significant downregulation of several markers of inflammation was associated with IVA337. Despite its anti-inflammatory and antifibrotic properties, IVA337 did not interfere with wound closure. In vitro effects of IVA337 included attenuation of transcription of ECM genes and alteration of canonical and non-canonical TGF-.BETA. signalling pathways. CONCLUSIONS: These findings indicate that simultaneous activation of all three PPAR isoforms exerts a dampening effect on inflammation and fibrosis, making IVA337 a potentially effective therapeutic candidate in the treatment of fibrotic diseases including SSc.

Showing 1 to 1 of 1 entries

Previous1Next